1. Home
  2. FNLC vs EOLS Comparison

FNLC vs EOLS Comparison

Compare FNLC & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Bancorp Inc  (ME)

FNLC

First Bancorp Inc (ME)

HOLD

Current Price

$29.50

Market Cap

306.9M

Sector

Finance

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$4.31

Market Cap

304.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNLC
EOLS
Founded
1864
2012
Country
US
US
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
306.9M
304.0M
IPO Year
1995
2018

Fundamental Metrics

Financial Performance
Metric
FNLC
EOLS
Price
$29.50
$4.31
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$17.40
AVG Volume (30 Days)
15.8K
925.7K
Earning Date
04-22-2026
03-29-2026
Dividend Yield
5.12%
N/A
EPS Growth
N/A
25.00
EPS
2.16
N/A
Revenue
N/A
$266,274,000.00
Revenue This Year
N/A
$13.57
Revenue Next Year
N/A
$11.39
P/E Ratio
$13.40
N/A
Revenue Growth
N/A
31.76
52 Week Low
$22.11
$4.09
52 Week High
$30.33
$14.93

Technical Indicators

Market Signals
Indicator
FNLC
EOLS
Relative Strength Index (RSI) 57.75 34.32
Support Level $28.88 $4.25
Resistance Level $29.71 $4.50
Average True Range (ATR) 0.72 0.26
MACD 0.02 0.04
Stochastic Oscillator 64.29 26.00

Price Performance

Historical Comparison
FNLC
EOLS

About FNLC First Bancorp Inc (ME)

First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services including deposit accounts and consumer, commercial and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: